Area of research
Rheumatology · Immunology
Research interest
Research focused on Secukinumab and Psoriatic arthritis, with related work in Ankylosing spondylitis, Placebo, BASDAI. Notable publications include 'Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study', 'SAT0390 Secukinumab for The Treatment of Ankylosing Spondylitis: Comparative Effectiveness Results versus Currently Licensed Biologics from A Network Meta-Analysis', and 'OP0114 Secukinumab for The Treatment of Ankylosing Spondylitis: Comparative Effectiveness Results versus Adalimumab Using A Matching-Adjusted Indirect Comparison'.
Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study
AB0685 Secukinumab provides sustained improvements in work productivity and health related quality of life in patients with ankylosing spondylitis: long-term results from measure 1 and measure 2
AB0772 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved low disease activity related to psoriatic arthritis disease activity score (PASDAS)
FRI0521 Secukinumab provides sustained improvements in work productivity and health related quality of life in patients with active psoriatic arthritis: 2-year results from future 1 and future 2
SAT0480 Comparative effectiveness of secukinumab and infliximab in psoriatic arthritis assessed by matching-adjusted indirect comparison using pivotal phase 3 clinical trial data
THU0393 Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies
FRI0494 Secukinumab provides rapid and sustained pain relief in psoriatic arthritis: 2-year results from the future 2 study
SAT0390 Secukinumab for The Treatment of Ankylosing Spondylitis: Comparative Effectiveness Results versus Currently Licensed Biologics from A Network Meta-Analysis
OP0114 Secukinumab for The Treatment of Ankylosing Spondylitis: Comparative Effectiveness Results versus Adalimumab Using A Matching-Adjusted Indirect Comparison
THU0630 Treatment Failure, Treatment Switching and Health-Related Quality of Life in Patients with Ankylosing Spondylitis or Psoriatic Arthritis: Results from A Large Multinational Real-World Sample in Europe and The USA
THU0411 Fatigue in Patients with Ankylosing Spondylitis and Low Vitality in Those with Psoriatic Arthritis: Results from A Large Real-World Survey in Europe and The USA